SCHEMBL13342148

SCHEMBL13342148

CC(C)(C)NC(=O)CN(C(=O)c1ccccc1)S(C)(=O)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.52
HDAC6 Q9UBN7 6/20 0.52
HDAC3 O15379 2/20 0.52
HDAC2 Q92769 2/20 0.52
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
HSD11B1 P28845 2/20 0.42
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP2C9 P11712 1/20 0.41
EPHX1 P07099 1/20 0.41
POLB P06746 1/20 0.41
NPC1 O15118 2/20 0.40
LMNA P02545 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14393896 0.81 CTSL (0.44) CTSSHSD11B1SMN1; SMN2NPC1GAA
SCHEMBL12561256 0.80 HDAC1 (0.55) HDAC1HDAC6HDAC3HDAC2CTSS
SCHEMBL12376711 0.75 GAA (0.61) MAPTSMN1; SMN2CYP2C9POLBLMNA
SCHEMBL23733160 0.74 HSD11B1 (0.45) HSD11B1MAPTSMN1; SMN2POLBTSHR
SCHEMBL1526960 0.70 HDAC1 (0.48) HDAC1HDAC6HDAC3HDAC2CTSS
SCHEMBL25702592 0.69 HSD11B1 (0.46) CTSSCTSKHSD11B1POLBNR3C2
SCHEMBL13564416 0.67 ALDH1A1 (0.35) HDAC1HDAC6HDAC3HDAC2SMN1; SMN2
SCHEMBL134145 0.67 HSD11B1 (0.67) HSD11B1POLBNPC1TSHRKMT2A
SCHEMBL31470191 0.66 CTSS (0.59) HDAC1HDAC6HDAC3HDAC2CTSS
SCHEMBL408310 0.66 CYP2C9 (0.67) HDAC1HDAC6HDAC3HDAC2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 HDAC1 2198/4885HDAC6 2092/4885HDAC3 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.